The Leukemia & Lymphoma Society is laying the groundwork for PedAL, a global precision master clinical trial, to usher in a new era of treatment for relapsed and refractory pediatric leukemias. By shifting the paradigm for pediatric leukemia clinical trials to one that is internationally-integrated and collaborative, LLS PedAL aims to accelerate the testing of new precision medicine therapies and change how novel, targeted therapies are developed for the treatment of children with relapsed leukemia.
LLS PedAL will be an integrated multi-site, multi-therapy master clinical trial with the goal of matching patients to precision treatment based on their unique tumor biology. LLS PedAL seeks to break down silos across sectors, scientific disciplines, institutions, and countries, including the creation of a regulatory and technical infrastructure that fosters large-scale data aggregation and sharing. This new model, which was created based on LLS’s experience launching its Beat AML Master Clinical Trial, aims to create operational and cost efficiencies in study management, make data from different sources interoperable, facilitate easy identification of appropriate patients for new therapies, and consolidate clinical and scientific data from academic medical centers and cooperative groups across the United States and Europe.